Biotech | February 21, 2022
Valneva receives funding for Covid-19 vaccine from Scotland
The grants are expected to be received over the next three years, commencing March 2022
The grants are expected to be received over the next three years, commencing March 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Evonik invests in start-up to improve patient recovery after open-chest surgery
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Adds five years of market exclusivity on approval
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
